Sun Pharma falls on anti-diabetes drug recall

Shares in Sun Pharmaceutical Industries Ltd fall as much as 2.8 percent after the

RELATED ARTICLES

US Food and Drug Administration said the drug maker was voluntarily recalling 2,528 bottles of its generic version of diabetes drug Glumetza from US-based Santarus Inc.

Sun began recalling the bottles of metformin HCL extended-release tables in the United States on January 28, 2014, after it received a customer complaint that one of the bottles contained tablets of epilepsy drug Gabapentin, the FDA said in a release on its web site.

A Sun spokeswoman confirmed the recall on Monday morning, adding that the company did not expect a significant impact.

The FDA classified the recall as a "Class II," which signifies a remote chance of severe adverse consequences or death due to the product flaw.

The Sun recall comes as shares in Ranbaxy Laboratories Ltd fell as much as 3.8 percent on Monday after the drug maker recalled more than 64,000 bottles of the generic version of a cholesterol-lowering drug in the United States after a doseage mix-up was detected.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • But what’s the big deal about Modi’s first hundred days?

    That Indians believe more in symbolism than substance is a fact that is well acknowledged and chronicled.

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Chander Mohan Sethi

CMD, Reckitt Benckiser India

COLUMNIST

Urs Schöttli

West Asia turmoil worries east Asia

From Beijing to Jakarta, from Manila to Tokyo, east Asian ...

Parvez Imam

Sowing the seeds of love for hatred

No wonder we have a whole lot of talking going ...

Dharmendra Khandal

Time to protect our endangered wildlife species

After 65 million years of existence, the earth’s biodiversity is ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture